Haptoglobin genotype and its role in diabetic cardiovascular disease

Journal of Cardiovascular Translational Research

Volumn 5, Issue 4, 2012, Pages 423-435

  Costacou, Tina ^a   Levy, Andrew P ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cardiovascular disease; Diabetes; Haptoglobin genotype

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; CONJUGATED ESTROGEN; HAPTOGLOBIN; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPTOGLOBIN GENE; HEART PROTECTION; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; RISK REDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; GENETIC PREDISPOSITION TO DISEASE; HAPTOGLOBINS; HUMANS; INCIDENCE; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; PROTEIN CONFORMATION; RISK ASSESSMENT; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866098563     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9361-z     Document Type: Article

References (112)

1. Preis, S. R., Hwang, S. J., Coady, S., Pencina, M. J., D'Agostino, R. B., Sr., Savage, P. J., Levy, D., & Fox, C. S. (2009). Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation, 119, 1728-1735.
2. Franco, O. H., Steyerberg, E. W., Hu, F. B., Mackenbach, J., & Nusselder, W. (2007). Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Archives of Internal Medicine, 167, 1145-1151.
3. Gu, K., Cowie, C. C., & Harris, M. I. (1998). Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care, 21, 1138-1145.
4. Centers for Disease Control and Prevention. (2011). National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention.
5. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Data computed by personnel in the CDC's Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion.
6. Gregg, E. W., Gu, Q., Cheng, Y. J., Narayan, K. M., & Cowie, C. C. (2007). Mortality trends in men and women with diabetes, 1971 to 2000. Annals of Internal Medicine, 147, 149-155.
7. Pambianco, G., Costacou, T., Ellis, D., Becker, D. J., Klein, R., & Orchard, T. J. (2006). The 30-year natural history of type 1 diabetes complications. The Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes, 55, 1463-1469.
8. Imperatore, G., Cadwell, B. L., Geiss, L., Saadinne, J. B.,Williams, D. E., Ford, E. S., Thompson, T. J., Narayan, K.M.,& Gregg, E.W. (2004). Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination surveys, 1971-2000. American Journal of Epidemiology, 160, 531-539.
9. Krolewski, A. S., Warram, J. H., Christlieb, A. R., Busick, E. J., & Kahn, C. R. (1985). The changing natural history of nephropathy in type I diabetes. American Journal of Medicine, 78, 785-794.
10. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, D. C., Jr., Bigger, J. T., Buse, J. B., Cushman, W. C., Genuth, S., Ismail- Beigi, F., Grimm, R. H., Jr., Probstfield, J. L., Simons-Morton, D. G., & Friedewald, W. T. (2008). Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine, 358, 2545-2559.
11. ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L., Mancia, G., Mogensen, C. E., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bompoint, S., de Galan, B. E., Joshi, R., & Travert, F. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 358(24), 2560-2572.
12. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R., Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., Huang, G. D., & VADT Investigators. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine, 360(2), 129-139.
13. Marre, M. (1999). Genetics and the prediction of complications in type 1 diabetes. Diabetes Care, 22(Suppl. 2), B53-B58.
14. Ruiz, J. (1997). Diabetes mellitus and late complications: influence of genetic factors. Diabetes & Metabolism, 23(Suppl. 2), 57-63.
15. Pignoli, P., Tremoli, E., Poli, A., et al. (1986). Intimal plus medial thickness of arterial wall: a direct measurement with ultrasound imaging. Circulation, 74, 1399-1406.
16. Persson, J., Stavenow, L., Wikstrand, J., et al. (1992). Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arteriosclerosis and Thrombosis, 12, 261-266.
17. Carr, J. J., Crouse, J. R., Goff, D. C., Burke, G. L., et al. (2000). Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. American Journal of Roentgenology, 174, 915-921.
18. Raggi, P., Callister, T. Q., Cooil, B., He, Z. X., Lippolis, N. J., Russo, D. J., Zelinger, A., & Mahmarian, J. J. (2000). Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation, 101, 850-855.
19. Edmonds, M. E. (2000). Medial arterial calcification and diabetes mellitus. Zeitschrift fur Kardiologie, 89(Suppl. 2), 101-104.
20. Lange, L. A., Bowden, D. W., Langefeld, C. D., Wagenknecht, L. E., Carr, J. J., Rich, S. S., Riley, W. A., & Freedman, B. I. (2002). Heritability of carotid artery intima-medial thickness in type 2 diabetes. Stroke, 33(7), 1876-1881.
21. Wagenknecht, L. E., Bowden, D. W., Carr, J. J., Langefeld, C. D., Freedman, B. I., & Rich, S. S. (2001). Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes, 50, 861-866.
22. Polonovski, M., & Jayle, M. F. (1938). Existence dans le plasma sanguine d'une substance activant l'action peroxydasique de l'hé moglobine. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales, 129, 457-460.
23. Polonovski, M., & Jayle, M. F. (1940). Sur la préparation d'une nouvelle fraction des protéines plasmatiques l'haptoglobine. Compt Rend Acad Sci, 211, 517-519.
24. Kalmovarin, N., Friedrichs,W. E., O'Brien, H. V., Linehan, L. A., Bowman, B. H., & Yang, F. (1991). Extrahepatic expression of plasma protein genes during inflammation. Inflammation, 15, 369-379.
25. Yang, F., Friedrichs,W. E., Navarijo-Ashbaugh, A. L., deGraffenried, L. A., Bowman, B. H., & Coalson, J. J. (1995). Cell type-specific and inflammatory-induced expression of haptoglobin gene in lung. Laboratory Investigation, 73(3), 433-440.
26. Friedrichs, W. E., Navarijo-Ashbaugh, A. L., Bowman, B. H., & Yang, F. (1995). Expression and inflammatory regulation of haptoglobin gene in adipocytes. Biochemical and Biophysical Research Communications, 209, 250-256.
27. Kanakoudi, F., Drossou, V., Tzimouli, V., Diamanti, E., Konstantinidis, T., Germenis, A., & Kremenopoulos, G. (1995). Serum concentrations of 10 acute-phase proteins in healthy term and preterm infants from birth to age 6 months. Clinical Chemistry, 41, 605-608.
28. Gabay, C., & Kushner, I. (1999). Mechanisms of disease: acutephase proteins and other systemic responses to inflammation. New Engl J Med, 340, 448-454.
29. Bowman, B. H., & Kurosky, A. (1982). Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Advances in Human Genetics, 12, 189-261.
30. Langlois, M. R., & Delanghe, J. R. (1996). Biological and clinical significance of haptoglobin polymorphism in humans. Clinical Chemistry, 42, 1589-1600.
31. Graversen, J. H., Madsen, M., & Moestrup, S. K. (2002). CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. The International Journal of Biochemistry & Cell Biology, 34(4), 309-314.
32. Garby, L., & Noyes, W. D. (1959). Studies on hemoglobin metabolism: I. The kinetic properties of the plasma hemoglobin pool in normal man. The Journal of Clinical Investigation, 38, 1479-1483.
33. Sadrzadeh, S. M. H., Graf, E., Panter, S. S., Hallaway, P. E., & Eaton, J. W. (1984). Hemoglobin: a biologic Fenton reagent. Journal of Biological Chemistry, 259, 14354-14356.
34. Nakhoul, F. M., Miller-Lotan, R., Awad, H., Asleh, R., Kheir, J., Nakhoul, N., Asaf, R., Abu-Saleh, N., & Levy, A. P. (2009). Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus. American Journal of Physiology. Renal Physiology, 296, F830-F838.
35. Dessy, C., & Ferron, O. (2004). Pathophysiological roles of nitric oxide: in the heart and the coronary vasculature. Current Medical Chemistry - Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 3, 207-216.
36. Azarov, I., He, X., Jeffers, A., Basu, S., Ucer, B., Hantgan, R. R., Levy, A., & Kim-Shapiro, D. B. (2008). Rate of nitric oxide scavenging by hemoglobin bound to haptoglobin. Nitric Oxide, 18, 296-302.
37. Orchard, T. J., Costacou, T., Kretowski, A., & Nesto, R. W. (2006). Type 1 diabetes and coronary artery disease. Diabetes Care, 29, 2528-2538.
38. Yu, Y., Thorpe, S. R., Jenkins, A. J., Shaw, J. N., Sochaski, M. A., McGee, D., Aston, C. E., Orchard, T. J., Silvers, N., Peng, Y. G., McKnight, J. A., Baynes, J. W., Lyons, T. J., & The DCCT/EDIC Research Group. (2006). Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia, 49, 2488-2498.
39. Endemann, D. H., & Schiffrin, E. L. (2004). Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Current Hypertension Reports, 6, 85-89.
40. Smithies, O. (1955). Zone electrophoresis in starch gels: group variation in the serum proteins of normal human adults. The Biochemical Journal, 61, 629-641.
41. Wejman, J. C., Hovsepian, D.,Wall, J. S., Hainfeld, J. F.,&Greer, J. (1984). Structure and assembly of haptoglobin polymers by electron microscopy. Journal of Molecular Biology, 174, 343-368.
42. Carter, K., & Worwood, M. (2007). Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. International Journal of Laboratory Hematology, 29 (2), 92-110.
43. Asleh, R., Marsh, S., Shilkrut, M., Binah, O., Guetta, J., Lejbkowicz, F., Enav, B., Shehadeh, N., Kanter, Y., Lache, O., Cohen, O., Levy, N. S., & Levy, A. P. (2003). Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circulation Research, 92, 1193-1200.
44. Melamed-Frank, M., Lache, O., Enav, B. I., Szafranek, T., Levy, N. S., Ricklis, R. M., & Levy, A. P. (2001). Structure-function analysis of the antioxidant properties of haptoglobin. Blood, 98, 3693-3698.
45. Asleh, R., Guetta, J., Kalet-Litman, S., Miller-Lotan, R., & Levy, A. P. (2005). Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circulation Research, 96, 435-441.
46. Levy, A. P., Purushothaman, K. R., Levy, N. S., Purushothaman, M., Strauss, M., Asleh, R., Marsh, S., Cohen, O., Moestrup, S. K., Moller, H. J., Zias, E. A., Benhayon, D., Fuster, V., & Moreno, P. R. (2007). Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circulation Research, 101, 106-110.
47. Asleh, R., Blum, S., Kalet-Litman, S., Alshiek, J., Miller-Lotan, R., Asaf, R., Rock, W., Aviram, M., Milman, U., Shapira, C., Abassi, Z., & Levy, A. P. (2008). Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes, 57, 2794-2800.
48. Kunitake, S. T., Carilli, C. T., Lau, K., Protter, A. A., Naya- Vigne, J., & Kane, J. P. (1994). Identification of proteins associated with apolipoprotein A-I-containing lipoproteins purified by selected-affinity immunosorption. Biochemistry, 33, 1988-1993.
49. Porta, A., Cassano, E., Balestrieri, M., Bianco, M., Picone, R., De Stefano, C., & Abrescia, P. (1999). Haptoglobin transport into human ovarian follicles and its binding to apolipoprotein A-1. Zygote, 7, 67-77.
50. Spagnuolo, M. S., Cigliano, L., D'Andrea, L. D., Pedone, C., & Abrescia, P. (2005). Assignment of the binding site for haptoglobin on apolipoprotein A-I. Journal of Biological Chemistry, 280, 1193-1198.
51. Watanabe, J., Chou, K. J., Liao, J. C., Miao, Y., Meng, H. H., Ge, H., Grijalva, V., Hama, S., Kozak, K., Buga, G., Whitelegge, J. P., Lee, T. D., Farias-Eisner, R., Navab, M., Fogelman, A. M., & Reddy, S. T. (2007). Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. Journal of Biological Chemistry, 282, 23698-23707.
52. Watanabe, J., Grijalva, V., Hama, S., Barbour, K., Berger, F. G., Navab, M., Fogelman, A. M., & Reddy, S. T. (2009). Hemoglobin and its scavenger protein haptoglobin associate with apoA-1- containing particles and influence the inflammatory properties and function of high density lipoprotein. Journal of Biological Chemistry, 284, 18292-18301.
53. Asleh, R., & Levy, A. P. (2005). In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vascular Health and Risk Management, 1, 19-28.
54. Conway, B., Fried, L., & Orchard, T. J. (2008). Hemoglobin and overt nephropathy complications in type 1 diabetes. Annals of Epidemiology, 18, 147-155.
55. Levy, A. P., Hochberg, I., Jablonski, K., Resnick, H. E., Lee, E. T., Best, L., Howard, B. V.,& Strong Heart Study. (2002). Haptoglobin genotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. Journal of the American College of Cardiology, 40, 1984-1990.
56. Roguin, A., Koch, W., Kastrati, A., Aronson, D., Schomig, A., & Levy, A. P. (2003). Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care, 26, 2628-2631.
57. Suleiman, M., Aronson, D., Asleh, R., Kapeliovich, M. R., Roguin, A., Meisel, S. R., Shochat, M., Sulieman, A., Reisner, S. A., Markiewicz, W., Hammerman, H., Lotan, R., Levy, N. S., & Levy, A. P. (2005). Haptoglobin polymorphism predicts 30- day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes, 54, 2802-2806.
58. Milman, U., Blum, S., Shapira, C., Aronson, D., Miller-Lotan, R., Anbinder, Y., Alshiek, J., Bennett, L., Kostenko, M., Landau, M., Keidar, S., Levy, Y., Khemlin, A., Radan, A., & Levy, A. P. (2008). Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 341-347.
59. Costacou, T., Ferrell, R. E., & Orchard, T. J. (2008). Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes, 57, 1702-1706.
60. Simpson, M., Snell-Bergeon, J. K., Kinney, G. L., Lache, O., Miller-Lotan, R., Anbinder, Y., Rewers, M. J., & Levy, A. P. (2011). Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovascular Diabetology, 10, 99.
61. Levy, A. P., Levy, J. E., Kalet-Litman, S., Miller-Lotan, R., Levy, N. S., Asaf, R., Guetta, J., Yang, C., Purushothaman, K. R., Fuster, V., & Moreno, P. R. (2007). Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 134-140.
62. Kalet-Litman, S., Moreno, P. R., & Levy, A. P. (2010). The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis, 209, 28-31.
63. Moreno, P. R., Purushothaman, K. R., Purushothaman,M., Muntner, P., Levy, N. S., Fuster, V., Fallon, J. T., Lento, P. A.,Winterstern, A., & Levy, A. P. (2008). Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. Journal of the American College of Cardiology, 52, 1049-1051.
64. Lioupis, C., Barbatis, C., Drougou, A., Koliaraki, V., Mamalaki, A., Klonaris, C., Georgopoulos, S., Andrikopoulos, V., & Bastounis, E. (2011). Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques. Atherosclerosis, 216, 131-138.
65. Asleh, R., Miller-Lotan, R., Aviram, M., Hayek, T., Yulish, M., Levy, J. E., Miller, B., Blum, S., Milman, U., Shapira, C., & Levy, A. P. (2006). Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circulation Research, 99, 1419-1425.
66. Orchard, T. J. (1991). Dyslipoproteinemia and diabetes. Endocrinology and Metabolism Clinics of North America, 19, 361-380.
67. Costacou, T., Evans, R. W., Orchard, T. J. (2011) High density lipoprotein cholesterol: is higher always better? Journal of Clinical Lipidology, 5(5), 387-394. PMCID: PMC3190122.
68. Brouwers, A., Langlois, M., Delanghe, J., Billiet, J., De Buyzere, M., Vercaemst, R., Rietzschel, E., Bernard, D., & Blaton, V. (2004). Oxidized low-density lipoprotein, iron stores, and haptoglobin polymorphism. Atherosclerosis, 176(1), 189-195.
69. Libby, P., Ridker, P. M., & Hansson, G. K. (2009). Inflammation in atherosclerosis: from pathophysiology to practice. Journal of the American College of Cardiology, 54, 2129-2138.
70. Philippidis, P., Mason, J. C., Evans, B. J., Nadra, I., Taylor, K. M., Haskard, D. O., & Landis, R. C. (2004). Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte- macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circulation Research, 94(1), 119-126.
71. Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., Parfrey, P., Pfeffer, M., Raij, L., Spinosa, D. J., Wilson, P. W., & American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. (2003). Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 42, 1050-1065.
72. Dinneen, S. F., & Gerstein, H. C. (1997). The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Archives of Internal Medicine, 157, 1413-1418.
73. Jensen, T., Borch-Johnsen, K., Kofoed-Enevoldsen, A., & Deckert, T. (1987). Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia, 30, 144-148.
74. Messent, J. W. C., Elliott, T. G., Hill, R. D., Jarrett, R. J., Keen, H., & Viberti, G. C. (1992). Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twentythree year follow-up study. Kidney International, 41, 836-839.
75. Tuomilehto, J., Borch-Johnsen, K., Molarius, A., Forsén, T., Rastenyte, D., Sarti, C., & Reunanen, A. (1998). Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia, 41, 784-790.
76. Torffvit, O., Lövestam-Adrian, M., Agardh, E., & Agardh, C.-D. (2005). Nephropathy, but not retinopathy, is associated with the development of heart disease in type I diabetes: a 12-year observation study of 462 patients. Diabetic Medicine, 22, 723-729.
77. Costacou, T., Ferrell, R. E., Ellis, D., & Orchard, T. J. (2009). Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes, 58, 2904-2909.
78. Kramer, H. J., Nguyen, Q. D., Curhan, G., & Hsu, C. Y. (2003). Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA, 289, 3273-3277.
79. Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., & Holman, R. R. (2006). UKPDS Study risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes, 55, 1832-1839.
80. Costacou, T., Ellis, D., Fried, L., & Orchard, T. J. (2007). Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. American Journal of Kidney Diseases, 50, 721-732.
81. Hiller, R., Sperduto, R. D., Podgor, M. J., Ferris, F. L., 3rd, & Wilson, P. W. (1988). Diabetic retinopathy and cardiovascular disease in type II diabetics. The Framingham Heart Study and the Framingham Eye Study. American Journal of Epidemiology, 128 (2), 402-409.
82. Wong, T. Y., Klein, R., Klein, B. E. K., Tielsch, J. M., Hubbard, L., & Nieto, F. J. (2001). Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Survey of Ophthalmology, 46, 59-80.
83. Cheung, N., Bluemke, D. A., Klein, R., Sharrett, A. R., Islam, F. M., Cotch, M. F., Klein, B. E., Criqui, M. H., & Wong, T. Y. (2007). Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. Journal of the American College of Cardiology, 50, 48-55.
84. Wong, T. Y., Wong, T. Y., Cheung, N., Islam, A. F. M., Klein, R., Criqui, M. H., Cotch, M. F., Carr, J. J., Klein, B. E., & Sharrett, A. R. (2008). Relation of retinopathy to coronary artery calcification: the multi-ethnic study of atherosclerosis. American Journal of Epidemiology, 167(1), 51-58.
85. Kawasaki, R., Cheung, N., Islam, F. M., Klein, R., Klein, B. E., Cotch, M. F., Sharrett, A. R., O'Leary, D., Wong, T. Y., & Multi-Ethnic Study of Atherosclerosis. (2011). Is diabetic retinopathy related to subclinical cardiovascular disease? Ophthalmology, 118, 860-865.
86. Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation Research, 107(9), 1058-1070.
87. Goldenberg-Cohen, N., Gabbay, M., Dratviman-Storobinsky, O., Reich, E., Axer-Siegel, R., Weinberger, D., & Gabbay, U. (2011). Does haptoglobin genotype affect early onset of diabetic retinopathy in patients with type 2 diabetes? Retina, 31(8), 1574-1580.
88. Rapola, J. M., Virtamo, J., Haukka, J. K., Heinonen, O. P., Albanes, D., Taylor, P. R., & Huttunen, J. K. (1996). Effect of vitamin E and beta carotene on the incidence of angina pectoris: a randomized, double-blind, controlled trial. JAMA, 275, 693-698.
89. Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., Sleight, P., & for the Heart Outcomes Prevention Evaluation Study Investigators. (2000). Vitamin E supplementation and cardiovascular events in high-risk patients. The New England Journal of Medicine, 342, 154-160.
90. Lee, I. M., Cook, N. R., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005). Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA, 294(1), 56-65.
91. de Gaetano, G., & for the Collaborative Group of the Primary Prevention Project. (2001). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet, 357, 89-95.
92. Virtamo, J., Rapola, J. M., Ripatti, S., Heinonen, O. P., Taylor, P. R., Albanes, D., & Huttunen, J. K. (1998). Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Archives of Internal Medicine, 158, 668-675.
93. Hodis, H. N., Mack, W. J., LaBree, L., Mahrer, P. R., Sevanian, A., Liu, C. R., Liu, C. H., Hwang, J., Selzer, R. H., Azen, S. P., & for the VEAPS Research Group. (2002). Alpha-tocopherol supplementation in healthy individuals reduces low density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation, 106, 1453-1459.
94. Cook, N. R., Albert, C. M., Gaziano, J. M., Zaharris, E., MacFadyen, J., Danielson, E., Buring, J. E., & Manson, J. E. (2007). A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Archives of Internal Medicine, 167, 1610-1618.
95. Levy, A. P., Gerstein, H., Lotan, R., Ratner, R., McQueen, M., Lonn, E., & Pogue, J. (2004). The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care, 27, 2767.
96. Blum, S., Vardi, M., Levy, N. S., Miller-Lotan, R., & Levy, A. P. (2010). The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis, 211, 25-27.
97. Blum, S., Milman, U., Shapira, C., Miller-Lotan, R., Bennett, L., Kostenko, M., Landau, M., Keidar, S., Levy, Y., Khemlin, A., Radan, A., & Levy, A. P. (2008). Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, e18-e20.
98. Blum, S., Milman, U., Shapira, C., Levy, N. S., Miller-Lotan, R., Levy, A. P. (2010) Vitamin E supplementation may provide cardiovascular benefit to Hp 2-2 diabetic individuals over and above that which can be obtained by treating to target for LDL and HbA1c. Circulation, 122, A10490 (abstract).
99. Engelen, W., Manuel-y-Keenoy, B., Vertommen, J., De Leeuw, I., & Van Gaal, L. (2005). Effects of micronized finofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus. Diabetes & Metabolism, 31, 197-204.
100. Farbstein, D., Blum, S., Pollak, M., Asaf, R., Viener, H. L., Lache, O., Asleh, R., Miller-Lotan, R., Barkay, I., Star, M., Schwartz, A., Kalet-Littman, S., Ozeri, D., Vaya, J., Tavori, H., Vardi, M., Laor, A., Bucher, S. E., Anbinder, Y., Moskovich, D., Abbas, N., Perry, N., & Levy, A. P. (2011). Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. Atherosclerosis, 219, 240-244.
101. Levy, A. P., Friedenberg, P., Lotan, R., Ouyang, P., Tripputi, M., Higginson, L., Cobb, F. R., Tardif, J. C., Bittner, V., & Howard, B. V. (2004). The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care, 27 (4), 925-930.
102. Waters, D. D., Alderman, E. L., Hsia, J., Howard, B. V., Cobb, F. R., Rogers, W. J., Ouyang, P., Thompson, P., Tardif, J. C., Higginson, L., Bittner, V., Steffes, M., Gordon, D. J., Proschan, M., Younes, N., & Verter, J. I. (2002). Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA, 288, 2432-2440.
103. Mowri, H. O., Frei, B., & Keaney, J. F., Jr. (2000). Glucose enhancement of LDL oxidation is strictly metal ion dependent. Free Radical Biology & Medicine, 29(9), 814-824.
104. Asleh, R., & Levy, A. P. (2010). Divergent effects of alphatocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype. Antioxidants & Redox Signaling, 12(2), 209-217.
105. Klein, E. A., Thompson, I. M., Jr., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., Karp, D. D., Lieber, M. M., Walther, P. J., Klotz, L., Parsons, J. K., Chin, J. L., Darke, A. K., Lippman, S. M., Goodman, G. E., Meyskens, F. L., Jr., & Baker, L. H. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306(14), 1549-1556.
106. Heinonen, O. P., Albanes, D., Virtamo, J., Taylor, P. R., Huttunen, J. K., Hartman, A. M., Haapakoski, J., Malila, N., Rautalahti, M., Ripatti, S., Mäenpää, H., Teerenhovi, L., Koss, L., Virolainen, M., & Edwards, B. K. (1998). Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. Journal of the National Cancer Institute, 90(6), 440-446.
107. Gaziano, J. M., Glynn, R. J., Christen, W. G., Kurth, T., Belanger, C., MacFadyen, J., Bubes, V., Manson, J. E., Sesso, H. D., & Buring, J. E. (2009). Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA, 301(1), 52-62.
108. Lonn, E., Bosch, J., Yusuf, S., Sheridan, P., Pogue, J., Arnold, J. M., Ross, C., Arnold, A., Sleight, P., Probstfield, J., Dagenais, G. R., & HOPE and HOPE-TOO Trial Investigators. (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA, 293(11), 1338-1347.
109. Brigelius-Flohé, R., & Traber, M. G. (1999). Vitamin E: function and metabolism. The FASEB Journal, 13(10), 1145-1155.
110. Traber, M. G., Elsner, A., & Brigelius-Flohé, R. (1998). Synthetic as compared to natural vitamin E is preferentially excreted as α- CEHC in human urine: studies using deuterated α-tocopheryl acetates. FEBS, 437, 145-148.
111. Yamauchi, J., Iwamoto, T., Kida, S., Masushige, S., Yamada, K., & Esashi, T. (2001). Tocopherol-associated protein is a liganddependent transcriptional activator. Biochemical and Biophysical Research Communications, 285(2), 295-299.
112. Institute of Medicine (2000). Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington: National Academies Press.